Table 1.

Relationship between GAs and clinical outcomes

Group (n)ORR (%)OR (95% CI), P valueMedian PFS (95% CI), monthsPFS P value
FGFR2+ population (107)35.56.9 (6.2–9.6)
Alteration classificationFusion (92)34.81.25 (0.4–3.8), 0.707.0 (6.0–10.5)0.79
Rearrangement (15)40.06.9 (4.7–11.7)
FGFR2 partnerNon-BICC1 (76)36.80.82 (0.3–2.0), 0.659.0 (6.2–11.1)0.20
BICC1 (31)32.36.8 (2.6–8.9)
Tumor suppressorUnaltered (43)37.20.88 (0.4–2.0), 0.7611.7 (9.1–17.4)0.0003
Altered (64)34.46.8 (4.9–6.9)
BAP1Unaltered (68)30.91.7 (0.8–3.9), 0.199.1 (6.2–11.7)0.06
Altered (39)43.66.9 (4.7–8.9)
CDKN2A/BUnaltered (86)38.40.50 (0.2–1.5), 0.229.0 (6.4–11.1)0.03
Altered (21)23.86.4 (1.7–6.9)
PBRM1Unaltered (97)36.10.76 (0.2–3.1), 0.707.0 (6.8–10.5)0.05
Altered (10)30.04.7 (1.4–10.8)
TP53Unaltered (98)38.8a9.0 (6.8–11.1)0.0003
Altered (9)02.8 (1.4–6.8)
PIK3CAUnaltered (98)35.70.90 (0.2–3.8), 0.898.8 (6.4–10.5)0.10
Altered (9)33.35.2 (1.5–11.1)
IDH1Unaltered (102)36.30.44 (0.05–4.1), 0.476.9 (6.1–9.6)0.28
Altered (5)20.0NE (1.4–NE)
  • Abbreviation: NE, not estimated.

  • aModel did not converge.